The US Securities and Exchange Commission is charging beleaguered biotech company Theranos, its CEO Elizabeth Holmes, and its former president Ramesh Balwani with what it calls “massive fraud.”
Background: A few years ago, Theranos was an up-and-coming startup out of Silicon Valley with a young, charismatic CEO who wanted to revolutionize the blood testing industry. Investors bought into the idea, and by 2014, Theranos was valued at $9 billion. But in 2015, an investigation by the Wall Street Journal raised concerns about the validity of the company’s testing technology.
Bad blood: Theranos set out to make a cheap, simple test that required only a few drops of blood from a finger prick instead of a needle draw. But there’s little evidence that it actually developed the technology it was marketing, especially after a 2016 government report revealed a host of problems at the company.
The details: On Wednesday, the SEC said Theranos raised more than $700 million from investors through “an elaborate, years-long fraud” by exaggerating or making false statements about its technology, business, and financial performance.
What it means: Theranos and Holmes have agreed to settle the fraud charges. Holmes will pay a $500,000 penalty and will be stripped of control of the company she founded. She also has to return millions of Theranos shares and won’t be able to serve as an executive at a publicly traded company for 10 years.
What happened to the microfinance organization Kiva?
A group of strikers argue that the organization seems more focused on making money than creating change. Are they right?
How one elite university is approaching ChatGPT this school year
Why Yale never considered banning the technology.
Six ways that AI could change politics
A new era of AI-powered domestic politics may be coming. Watch for these milestones to know when it’s arrived.
Cryptography may offer a solution to the massive AI-labeling problem
An internet protocol called C2PA adds a “nutrition label” to images, video, and audio.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.